Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 89

1.

Variants in LRRC34 reveal distinct mechanisms for predisposition to papillary thyroid carcinoma.

Comiskey DF Jr, He H, Liyanarachchi S, Sheikh MS, Genutis LK, Hendrickson IV, Yu L, Brock PL, de la Chapelle A.

J Med Genet. 2020 Feb 12. pii: jmedgenet-2019-106554. doi: 10.1136/jmedgenet-2019-106554. [Epub ahead of print]

PMID:
32051256
2.

A Truncating Germline Mutation of TINF2 in Individuals with Thyroid Cancer or Melanoma Results in Longer Telomeres.

He H, Li W, Comiskey DF, Liyanarachchi S, Nieminen TT, Wang Y, DeLap KE, Brock P, de la Chapelle A.

Thyroid. 2020 Feb;30(2):204-213. doi: 10.1089/thy.2019.0156.

PMID:
31928178
3.

Genetic Characterization and Prognostic Relevance of Acquired Uniparental Disomies in Cytogenetically Normal Acute Myeloid Leukemia.

Walker CJ, Kohlschmidt J, Eisfeld AK, Mrózek K, Liyanarachchi S, Song C, Nicolet D, Blachly JS, Bill M, Papaioannou D, Oakes CC, Giacopelli B, Genutis LK, Maharry SE, Orwick S, Archer KJ, Powell BL, Kolitz JE, Uy GL, Wang ES, Carroll AJ, Stone RM, Byrd JC, de la Chapelle A, Bloomfield CD.

Clin Cancer Res. 2019 Nov 1;25(21):6524-6531. doi: 10.1158/1078-0432.CCR-19-0725. Epub 2019 Aug 2.

PMID:
31375516
4.

Estimated risk of progression of lentigo maligna to lentigo maligna melanoma.

Menzies SW, Liyanarachchi S, Coates E, Smith A, Cooke-Yarborough C, Lo S, Armstrong B, Scolyer RA, Guitera P.

Melanoma Res. 2019 May 14. doi: 10.1097/CMR.0000000000000619. [Epub ahead of print]

PMID:
31095041
5.

Identification of Rare Variants Predisposing to Thyroid Cancer.

Wang Y, Liyanarachchi S, Miller KE, Nieminen TT, Comiskey DF Jr, Li W, Brock P, Symer DE, Akagi K, DeLap KE, He H, Koboldt DC, de la Chapelle A.

Thyroid. 2019 Jul;29(7):946-955. doi: 10.1089/thy.2018.0736. Epub 2019 May 13.

PMID:
30957677
6.

Clinical characteristics of patients with colorectal cancer with double somatic mismatch repair mutations compared with Lynch syndrome.

Pearlman R, Haraldsdottir S, de la Chapelle A, Jonasson JG, Liyanarachchi S, Frankel WL, Rafnar T, Stefansson K, Pritchard CC, Hampel H.

J Med Genet. 2019 Jul;56(7):462-470. doi: 10.1136/jmedgenet-2018-105698. Epub 2019 Mar 15.

7.

Risk Haplotypes Uniquely Associated with Radioiodine-Refractory Thyroid Cancer Patients of High African Ancestry.

Hurst Z, Liyanarachchi S, He H, Brock P, Sipos J, Nabhan F, Kebebew E, Green P, Cote GJ, Sherman S, Walker CJ, Chang YS, Xue S, Hollingsworth B, Li W, Genutis L, Menq E, de la Chapelle A, Jhiang SM.

Thyroid. 2019 Apr;29(4):530-539. doi: 10.1089/thy.2018.0687. Epub 2019 Feb 13.

PMID:
30654714
8.

Fine mapping of 14q13 reveals novel variants associated with different histological subtypes of papillary thyroid carcinoma.

Jendrzejewski J, Liyanarachchi S, Eiterman A, Thomas A, He H, Nagy R, Senter L, Sworczak K, de la Chapelle A.

Int J Cancer. 2019 Feb 1;144(3):503-512. doi: 10.1002/ijc.31933. Epub 2018 Dec 3.

9.

Genome-wide association study identifies an acute myeloid leukemia susceptibility locus near BICRA.

Walker CJ, Oakes CC, Genutis LK, Giacopelli B, Liyanarachchi S, Nicolet D, Eisfeld AK, Scholz M, Brock P, Kohlschmidt J, Mrózek K, Bill M, Carroll AJ, Kolitz JE, Powell BL, Wang ES, Niederwieser DW, Stone RM, Byrd JC, Schwind S, de la Chapelle A, Bloomfield CD.

Leukemia. 2019 Mar;33(3):771-775. doi: 10.1038/s41375-018-0281-z. Epub 2018 Oct 5. No abstract available.

10.

NF-κB inhibition rescues cardiac function by remodeling calcium genes in a Duchenne muscular dystrophy model.

Peterson JM, Wang DJ, Shettigar V, Roof SR, Canan BD, Bakkar N, Shintaku J, Gu JM, Little SC, Ratnam NM, Londhe P, Lu L, Gaw CE, Petrosino JM, Liyanarachchi S, Wang H, Janssen PML, Davis JP, Ziolo MT, Sharma SM, Guttridge DC.

Nat Commun. 2018 Aug 24;9(1):3431. doi: 10.1038/s41467-018-05910-1.

11.

The role of SMAD3 in the genetic predisposition to papillary thyroid carcinoma.

Wang Y, He H, Liyanarachchi S, Genutis LK, Li W, Yu L, Phay JE, Shen R, Brock P, de la Chapelle A.

Genet Med. 2018 Sep;20(9):927-935. doi: 10.1038/gim.2017.224. Epub 2018 Jan 4.

12.

The Role of NRG1 in the Predisposition to Papillary Thyroid Carcinoma.

He H, Li W, Liyanarachchi S, Wang Y, Yu L, Genutis LK, Maharry S, Phay JE, Shen R, Brock P, de la Chapelle A.

J Clin Endocrinol Metab. 2018 Apr 1;103(4):1369-1379. doi: 10.1210/jc.2017-01798.

13.

Penetrance of a rare familial mutation predisposing to papillary thyroid cancer.

Saporito D, Brock P, Hampel H, Sipos J, Fernandez S, Liyanarachchi S, de la Chapelle A, Nagy R.

Fam Cancer. 2018 Jul;17(3):431-434. doi: 10.1007/s10689-017-0048-0.

14.

A genome-wide association study yields five novel thyroid cancer risk loci.

Gudmundsson J, Thorleifsson G, Sigurdsson JK, Stefansdottir L, Jonasson JG, Gudjonsson SA, Gudbjartsson DF, Masson G, Johannsdottir H, Halldorsson GH, Stacey SN, Helgason H, Sulem P, Senter L, He H, Liyanarachchi S, Ringel MD, Aguillo E, Panadero A, Prats E, Garcia-Castaño A, De Juan A, Rivera F, Xu L, Kiemeney LA, Eyjolfsson GI, Sigurdardottir O, Olafsson I, Kristvinsson H, Netea-Maier RT, Jonsson T, Mayordomo JI, Plantinga TS, Hjartarson H, Hrafnkelsson J, Sturgis EM, Thorsteinsdottir U, Rafnar T, de la Chapelle A, Stefansson K.

Nat Commun. 2017 Feb 14;8:14517. doi: 10.1038/ncomms14517.

15.

Variants in microRNA genes in familial papillary thyroid carcinoma.

Tomsic J, Fultz R, Liyanarachchi S, Genutis LK, Wang Y, Li W, Volinia S, Jazdzewski K, He H, Wakely PE Jr, Senter L, de la Chapelle A.

Oncotarget. 2017 Jan 24;8(4):6475-6482. doi: 10.18632/oncotarget.14129.

16.

Prevalence and Spectrum of Germline Cancer Susceptibility Gene Mutations Among Patients With Early-Onset Colorectal Cancer.

Pearlman R, Frankel WL, Swanson B, Zhao W, Yilmaz A, Miller K, Bacher J, Bigley C, Nelsen L, Goodfellow PJ, Goldberg RM, Paskett E, Shields PG, Freudenheim JL, Stanich PP, Lattimer I, Arnold M, Liyanarachchi S, Kalady M, Heald B, Greenwood C, Paquette I, Prues M, Draper DJ, Lindeman C, Kuebler JP, Reynolds K, Brell JM, Shaper AA, Mahesh S, Buie N, Weeman K, Shine K, Haut M, Edwards J, Bastola S, Wickham K, Khanduja KS, Zacks R, Pritchard CC, Shirts BH, Jacobson A, Allen B, de la Chapelle A, Hampel H; Ohio Colorectal Cancer Prevention Initiative Study Group.

JAMA Oncol. 2017 Apr 1;3(4):464-471. doi: 10.1001/jamaoncol.2016.5194.

17.

Genome-Wide Expression Screening Discloses Long Noncoding RNAs Involved in Thyroid Carcinogenesis.

Liyanarachchi S, Li W, Yan P, Bundschuh R, Brock P, Senter L, Ringel MD, de la Chapelle A, He H.

J Clin Endocrinol Metab. 2016 Nov;101(11):4005-4013. Epub 2016 Jul 26.

18.

Dissection of the Major Hematopoietic Quantitative Trait Locus in Chromosome 6q23.3 Identifies miR-3662 as a Player in Hematopoiesis and Acute Myeloid Leukemia.

Maharry SE, Walker CJ, Liyanarachchi S, Mehta S, Patel M, Bainazar MA, Huang X, Lankenau MA, Hoag KW, Ranganathan P, Garzon R, Blachly JS, Guttridge DC, Bloomfield CD, de la Chapelle A, Eisfeld AK.

Cancer Discov. 2016 Sep;6(9):1036-51. doi: 10.1158/2159-8290.CD-16-0023. Epub 2016 Jun 27.

19.

Papillary Thyroid Carcinoma: Association Between Germline DNA Variant Markers and Clinical Parameters.

Jendrzejewski J, Liyanarachchi S, Nagy R, Senter L, Wakely PE, Thomas A, Nabhan F, He H, Li W, Sworczak K, Ringel MD, Kirschner LS, de la Chapelle A.

Thyroid. 2016 Sep;26(9):1276-84. doi: 10.1089/thy.2015.0665. Epub 2016 Jul 22.

20.

An NF-κB--EphrinA5-Dependent Communication between NG2(+) Interstitial Cells and Myoblasts Promotes Muscle Growth in Neonates.

Gu JM, Wang DJ, Peterson JM, Shintaku J, Liyanarachchi S, Coppola V, Frakes AE, Kaspar BK, Cornelison DD, Guttridge DC.

Dev Cell. 2016 Jan 25;36(2):215-24. doi: 10.1016/j.devcel.2015.12.018. Epub 2016 Jan 14.

21.

HABP2 G534E Variant in Papillary Thyroid Carcinoma.

Tomsic J, Fultz R, Liyanarachchi S, He H, Senter L, de la Chapelle A.

PLoS One. 2016 Jan 8;11(1):e0146315. doi: 10.1371/journal.pone.0146315. eCollection 2016.

22.

MicroRNA-3151 inactivates TP53 in BRAF-mutated human malignancies.

Lankenau MA, Patel R, Liyanarachchi S, Maharry SE, Hoag KW, Duggan M, Walker CJ, Markowitz J, Carson WE 3rd, Eisfeld AK, de la Chapelle A.

Proc Natl Acad Sci U S A. 2015 Dec 8;112(49):E6744-51. doi: 10.1073/pnas.1520390112. Epub 2015 Nov 18.

23.

Gene expression profiling of the human natural killer cell response to Fc receptor activation: unique enhancement in the presence of interleukin-12.

Campbell AR, Regan K, Bhave N, Pattanayak A, Parihar R, Stiff AR, Trikha P, Scoville SD, Liyanarachchi S, Kondadasula SV, Lele O, Davuluri R, Payne PR, Carson WE 3rd.

BMC Med Genomics. 2015 Oct 15;8:66. doi: 10.1186/s12920-015-0142-9.

24.

PTCSC3 Is Involved in Papillary Thyroid Carcinoma Development by Modulating S100A4 Gene Expression.

Jendrzejewski J, Thomas A, Liyanarachchi S, Eiterman A, Tomsic J, He H, Radomska HS, Li W, Nagy R, Sworczak K, de la Chapelle A.

J Clin Endocrinol Metab. 2015 Oct;100(10):E1370-7. doi: 10.1210/jc.2015-2247. Epub 2015 Aug 14.

25.

A germline mutation in SRRM2, a splicing factor gene, is implicated in papillary thyroid carcinoma predisposition.

Tomsic J, He H, Akagi K, Liyanarachchi S, Pan Q, Bertani B, Nagy R, Symer DE, Blencowe BJ, de la Chapelle A.

Sci Rep. 2015 Jul 2;5:10566. doi: 10.1038/srep10566.

26.

Multiple functional variants in long-range enhancer elements contribute to the risk of SNP rs965513 in thyroid cancer.

He H, Li W, Liyanarachchi S, Srinivas M, Wang Y, Akagi K, Wang Y, Wu D, Wang Q, Jin V, Symer DE, Shen R, Phay J, Nagy R, de la Chapelle A.

Proc Natl Acad Sci U S A. 2015 May 12;112(19):6128-33. doi: 10.1073/pnas.1506255112. Epub 2015 Apr 27.

27.

Genetic predisposition to papillary thyroid carcinoma: involvement of FOXE1, TSHR, and a novel lincRNA gene, PTCSC2.

He H, Li W, Liyanarachchi S, Jendrzejewski J, Srinivas M, Davuluri RV, Nagy R, de la Chapelle A.

J Clin Endocrinol Metab. 2015 Jan;100(1):E164-72. doi: 10.1210/jc.2014-2147.

28.

Identification of novel genetic Loci associated with thyroid peroxidase antibodies and clinical thyroid disease.

Medici M, Porcu E, Pistis G, Teumer A, Brown SJ, Jensen RA, Rawal R, Roef GL, Plantinga TS, Vermeulen SH, Lahti J, Simmonds MJ, Husemoen LL, Freathy RM, Shields BM, Pietzner D, Nagy R, Broer L, Chaker L, Korevaar TI, Plia MG, Sala C, Völker U, Richards JB, Sweep FC, Gieger C, Corre T, Kajantie E, Thuesen B, Taes YE, Visser WE, Hattersley AT, Kratzsch J, Hamilton A, Li W, Homuth G, Lobina M, Mariotti S, Soranzo N, Cocca M, Nauck M, Spielhagen C, Ross A, Arnold A, van de Bunt M, Liyanarachchi S, Heier M, Grabe HJ, Masciullo C, Galesloot TE, Lim EM, Reischl E, Leedman PJ, Lai S, Delitala A, Bremner AP, Philips DI, Beilby JP, Mulas A, Vocale M, Abecasis G, Forsen T, James A, Widen E, Hui J, Prokisch H, Rietzschel EE, Palotie A, Feddema P, Fletcher SJ, Schramm K, Rotter JI, Kluttig A, Radke D, Traglia M, Surdulescu GL, He H, Franklyn JA, Tiller D, Vaidya B, de Meyer T, Jørgensen T, Eriksson JG, O'Leary PC, Wichmann E, Hermus AR, Psaty BM, Ittermann T, Hofman A, Bosi E, Schlessinger D, Wallaschofski H, Pirastu N, Aulchenko YS, de la Chapelle A, Netea-Maier RT, Gough SC, Meyer Zu Schwabedissen H, Frayling TM, Kaufman JM, Linneberg A, Räikkönen K, Smit JW, Kiemeney LA, Rivadeneira F, Uitterlinden AG, Walsh JP, Meisinger C, den Heijer M, Visser TJ, Spector TD, Wilson SG, Völzke H, Cappola A, Toniolo D, Sanna S, Naitza S, Peeters RP.

PLoS Genet. 2014 Feb 27;10(2):e1004123. doi: 10.1371/journal.pgen.1004123. eCollection 2014 Feb.

29.

NRAS isoforms differentially affect downstream pathways, cell growth, and cell transformation.

Eisfeld AK, Schwind S, Hoag KW, Walker CJ, Liyanarachchi S, Patel R, Huang X, Markowitz J, Duan W, Otterson GA, Carson WE 3rd, Marcucci G, Bloomfield CD, de la Chapelle A.

Proc Natl Acad Sci U S A. 2014 Mar 18;111(11):4179-84. doi: 10.1073/pnas.1401727111. Epub 2014 Feb 28.

30.

Ultra-rare mutation in long-range enhancer predisposes to thyroid carcinoma with high penetrance.

He H, Li W, Wu D, Nagy R, Liyanarachchi S, Akagi K, Jendrzejewski J, Jiao H, Hoag K, Wen B, Srinivas M, Waidyaratne G, Wang R, Wojcicka A, Lattimer IR, Stachlewska E, Czetwertynska M, Dlugosinska J, Gierlikowski W, Ploski R, Krawczyk M, Jazdzewski K, Kere J, Symer DE, Jin V, Wang Q, de la Chapelle A.

PLoS One. 2013 May 14;8(5):e61920. doi: 10.1371/journal.pone.0061920. Print 2013. Erratum in: PLoS One. 2013;8(9). doi:10.1371/annotation/1cd4e899-2184-497b-b659-de1722b6d402.

31.

Cumulative risk impact of five genetic variants associated with papillary thyroid carcinoma.

Liyanarachchi S, Wojcicka A, Li W, Czetwertynska M, Stachlewska E, Nagy R, Hoag K, Wen B, Ploski R, Ringel MD, Kozłowicz-Gudzinska I, Gierlikowski W, Jazdzewski K, He H, de la Chapelle A.

Thyroid. 2013 Dec;23(12):1532-40. doi: 10.1089/thy.2013.0102. Epub 2013 Aug 29.

32.

SRGAP1 is a candidate gene for papillary thyroid carcinoma susceptibility.

He H, Bronisz A, Liyanarachchi S, Nagy R, Li W, Huang Y, Akagi K, Saji M, Kula D, Wojcicka A, Sebastian N, Wen B, Puch Z, Kalemba M, Stachlewska E, Czetwertynska M, Dlugosinska J, Dymecka K, Ploski R, Krawczyk M, Morrison PJ, Ringel MD, Kloos RT, Jazdzewski K, Symer DE, Vieland VJ, Ostrowski M, Jarząb B, de la Chapelle A.

J Clin Endocrinol Metab. 2013 May;98(5):E973-80. doi: 10.1210/jc.2012-3823. Epub 2013 Mar 28.

33.

Inherited cobalamin malabsorption. Mutations in three genes reveal functional and ethnic patterns.

Tanner SM, Sturm AC, Baack EC, Liyanarachchi S, de la Chapelle A.

Orphanet J Rare Dis. 2012 Aug 28;7:56. doi: 10.1186/1750-1172-7-56.

34.

Suppression of peroxiredoxin 4 in glioblastoma cells increases apoptosis and reduces tumor growth.

Kim TH, Song J, Alcantara Llaguno SR, Murnan E, Liyanarachchi S, Palanichamy K, Yi JY, Viapiano MS, Nakano I, Yoon SO, Wu H, Parada LF, Kwon CH.

PLoS One. 2012;7(8):e42818. doi: 10.1371/journal.pone.0042818. Epub 2012 Aug 15.

35.

The polymorphism rs944289 predisposes to papillary thyroid carcinoma through a large intergenic noncoding RNA gene of tumor suppressor type.

Jendrzejewski J, He H, Radomska HS, Li W, Tomsic J, Liyanarachchi S, Davuluri RV, Nagy R, de la Chapelle A.

Proc Natl Acad Sci U S A. 2012 May 29;109(22):8646-51. doi: 10.1073/pnas.1205654109. Epub 2012 May 14.

36.

Recurrent and founder mutations in the PMS2 gene.

Tomsic J, Senter L, Liyanarachchi S, Clendenning M, Vaughn CP, Jenkins MA, Hopper JL, Young J, Samowitz W, de la Chapelle A.

Clin Genet. 2013 Mar;83(3):238-43. doi: 10.1111/j.1399-0004.2012.01898.x. Epub 2012 Jun 4.

37.

miR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemia.

Eisfeld AK, Marcucci G, Maharry K, Schwind S, Radmacher MD, Nicolet D, Becker H, Mrózek K, Whitman SP, Metzeler KH, Mendler JH, Wu YZ, Liyanarachchi S, Patel R, Baer MR, Powell BL, Carter TH, Moore JO, Kolitz JE, Wetzler M, Caligiuri MA, Larson RA, Tanner SM, de la Chapelle A, Bloomfield CD.

Blood. 2012 Jul 12;120(2):249-58. doi: 10.1182/blood-2012-02-408492. Epub 2012 Apr 23.

38.

Heritable polymorphism predisposes to high BAALC expression in acute myeloid leukemia.

Eisfeld AK, Marcucci G, Liyanarachchi S, Döhner K, Schwind S, Maharry K, Leffel B, Döhner H, Radmacher MD, Bloomfield CD, Tanner SM, de la Chapelle A.

Proc Natl Acad Sci U S A. 2012 Apr 24;109(17):6668-73. doi: 10.1073/pnas.1203756109. Epub 2012 Apr 9.

39.

IKKα and alternative NF-κB regulate PGC-1β to promote oxidative muscle metabolism.

Bakkar N, Ladner K, Canan BD, Liyanarachchi S, Bal NC, Pant M, Periasamy M, Li Q, Janssen PM, Guttridge DC.

J Cell Biol. 2012 Feb 20;196(4):497-511. doi: 10.1083/jcb.201108118.

40.

MicroRNA signature in thyroid fine needle aspiration cytology applied to "atypia of undetermined significance" cases.

Shen R, Liyanarachchi S, Li W, Wakely PE Jr, Saji M, Huang J, Nagy R, Farrell T, Ringel MD, de la Chapelle A, Kloos RT, He H.

Thyroid. 2012 Jan;22(1):9-16. doi: 10.1089/thy.2011.0081. Epub 2011 Dec 2.

41.

Ancient founder mutation is responsible for Imerslund-Gräsbeck Syndrome among diverse ethnicities.

Beech CM, Liyanarachchi S, Shah NP, Sturm AC, Sadiq MF, de la Chapelle A, Tanner SM.

Orphanet J Rare Dis. 2011 Nov 13;6:74. doi: 10.1186/1750-1172-6-74.

42.

Glioma cell migration on three-dimensional nanofiber scaffolds is regulated by substrate topography and abolished by inhibition of STAT3 signaling.

Agudelo-Garcia PA, De Jesus JK, Williams SP, Nowicki MO, Chiocca EA, Liyanarachchi S, Li PK, Lannutti JJ, Johnson JK, Lawler SE, Viapiano MS.

Neoplasia. 2011 Sep;13(9):831-40.

43.

Telomere length and telomerase reverse transcriptase gene copy number in patients with papillary thyroid carcinoma.

Jendrzejewski J, Tomsic J, Lozanski G, Labanowska J, He H, Liyanarachchi S, Nagy R, Ringel MD, Kloos RT, Heerema NA, de la Chapelle A.

J Clin Endocrinol Metab. 2011 Nov;96(11):E1876-80. doi: 10.1210/jc.2011-1643. Epub 2011 Sep 7.

44.

Variants in the netrin-1 receptor UNC5C prevent apoptosis and increase risk of familial colorectal cancer.

Coissieux MM, Tomsic J, Castets M, Hampel H, Tuupanen S, Andrieu N, Comeras I, Drouet Y, Lasset C, Liyanarachchi S, Mazelin L, Puisieux A, Saurin JC, Scoazec JY, Wang Q, Aaltonen L, Tanner SM, de la Chapelle A, Bernet A, Mehlen P.

Gastroenterology. 2011 Dec;141(6):2039-46. doi: 10.1053/j.gastro.2011.08.041. Epub 2011 Sep 3.

45.

An American founder mutation in MLH1.

Tomsic J, Liyanarachchi S, Hampel H, Morak M, Thomas BC, Raymond VM, Chittenden A, Schackert HK, Gruber SB, Syngal S, Viel A, Holinski-Feder E, Thibodeau SN, de la Chapelle A.

Int J Cancer. 2012 May 1;130(9):2088-95. doi: 10.1002/ijc.26233. Epub 2011 Aug 30.

46.

Mutations in U4atac snRNA, a component of the minor spliceosome, in the developmental disorder MOPD I.

He H, Liyanarachchi S, Akagi K, Nagy R, Li J, Dietrich RC, Li W, Sebastian N, Wen B, Xin B, Singh J, Yan P, Alder H, Haan E, Wieczorek D, Albrecht B, Puffenberger E, Wang H, Westman JA, Padgett RA, Symer DE, de la Chapelle A.

Science. 2011 Apr 8;332(6026):238-40. doi: 10.1126/science.1200587.

47.

Histone deacetylases 9 and 10 are required for homologous recombination.

Kotian S, Liyanarachchi S, Zelent A, Parvin JD.

J Biol Chem. 2011 Mar 11;286(10):7722-6. doi: 10.1074/jbc.C110.194233. Epub 2011 Jan 18.

48.

Epigenetic silencing mediated through activated PI3K/AKT signaling in breast cancer.

Zuo T, Liu TM, Lan X, Weng YI, Shen R, Gu F, Huang YW, Liyanarachchi S, Deatherage DE, Hsu PY, Taslim C, Ramaswamy B, Shapiro CL, Lin HJ, Cheng AS, Jin VX, Huang TH.

Cancer Res. 2011 Mar 1;71(5):1752-62. doi: 10.1158/0008-5472.CAN-10-3573. Epub 2011 Jan 7.

49.

Thyroid hormone receptor beta (THRB) is a major target gene for microRNAs deregulated in papillary thyroid carcinoma (PTC).

Jazdzewski K, Boguslawska J, Jendrzejewski J, Liyanarachchi S, Pachucki J, Wardyn KA, Nauman A, de la Chapelle A.

J Clin Endocrinol Metab. 2011 Mar;96(3):E546-53. doi: 10.1210/jc.2010-1594. Epub 2010 Dec 15.

50.

Pheochromocytoma in rats with multiple endocrine neoplasia (MENX) shares gene expression patterns with human pheochromocytoma.

Molatore S, Liyanarachchi S, Irmler M, Perren A, Mannelli M, Ercolino T, Beuschlein F, Jarzab B, Wloch J, Ziaja J, Zoubaa S, Neff F, Beckers J, Höfler H, Atkinson MJ, Pellegata NS.

Proc Natl Acad Sci U S A. 2010 Oct 26;107(43):18493-8. doi: 10.1073/pnas.1003956107. Epub 2010 Oct 11.

Supplemental Content

Loading ...
Support Center